Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High- versus low-dose radiotherapy after short-course pegaspargase-containing chemotherapy in localized nasal NK/T-cell lymphoma
ChiCTR-TRC-14005218Phase 2Recruiting
- Sponsor
- Xijing Hospital
- Start
- Sep 2014
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegaspargase in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) (2 arms), sponsored by Xijing Hospital. Primary endpoint: 2-year locoregional recurrence-free survival. Started Sep 2014; status: recruiting.
02
Drugs
pegaspargase
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on ChiCTR-TRC-14005218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14005218.